Pet microbiome science is generating new diagnostic and therapeutic categories. Probiotics and prebiotics — long sold as supplements — are now being formalized as therapeutic interventions for gastrointestinal disease, dermatologic conditions, and immune support. Purina's FortiFlora, Royal Canin's Veterinary Diets, and emerging biotech entrants — AnimalBiome, Bench Biosciences, NomNomNow — are advancing fecal microbiota transplantation, strain-specific probiotic therapeutics, and microbiome diagnostic profiling. The category is expected to grow at 20%+ CAGR through 2030.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Pet Microbiome Market Size, Growth and Forecast 2025-2030
• Probiotics and Prebiotics — FortiFlora, Veterinary Diets, Supplements
• Fecal Microbiota Transplantation — Veterinary Applications
• Microbiome Diagnostic Profiling — AnimalBiome, NomNomNow
• Strain-Specific Probiotic Therapeutics in Development
• Microbiome Therapeutics for GI Disease — IBD, Acute Diarrhea
• Microbiome Therapeutics for Atopic Dermatitis
• Immune Modulation via Microbiome Intervention
• Functional Foods and Microbiome-Targeted Nutrition
• Investment and Partnership Activity in Pet Microbiome
Table of Contents
1. Executive Summary
2. Market Overview
3. Pet Microbiome Market Size, Growth and Forecast 2025-2030
4. Probiotics and Prebiotics
5. Fecal Microbiota Transplantation
6. Microbiome Diagnostic Profiling
7. Strain-Specific Therapeutics
8. GI Disease Applications
9. Atopic Dermatitis Applications
10. Immune Modulation
11. Functional Foods and Microbiome-Targeted Nutrition
12. Investment and Partnership Activity
13. Market Challenges and Risks
14. Competitive Landscape
15. Strategic Conclusions and Recommendations
16. Appendix
List of Tables
Table 1. Pet Microbiome Market Size and Forecast 2025-2030
Table 2. Probiotic and Prebiotic Sales by Manufacturer
Table 3. FMT Treatment Volume by Veterinary Practice
Table 4. Microbiome Diagnostic Test Sales by Provider
Table 5. Strain-Specific Therapeutic Pipeline Activity
Table 6. GI Disease Microbiome Intervention Trial Activity
Table 7. Atopic Dermatitis Microbiome Intervention Pipeline
Table 8. Immune Modulation Pipeline by Indication
Table 9. Functional Food Sales with Microbiome Claims
Table 10. Investment and Partnership Activity 2023-2026
Companies Profiled
AnimalBiome
Bench Biosciences
Boehringer Ingelheim Animal Health
Ceva Santé Animale
Elanco Animal Health
Hill's Pet Nutrition
Merck Animal Health
Nestlé Purina
NomNomNow
Royal Canin
Zoetis
